경희대학교 의과대학·의학전문대학원

- 강직성척추염, 류마티스 관절염, 루푸스 및 자가면역질환, 통풍 및 퇴행성관절염, 만성관절염

- 1999, 경희대학교 의과대학 졸업
- 2000 ~ 2004, 경희의료원 인턴, 내과 레지던트 수료
- 2004 ~ 2005, 경희의료원 류마티스내과 전임의
- 2002 ~ 2006, 경희대학교 의과대학 내과, 류마티스학 석,박사
- 2013 ~ 2014, 스탠포드 대학교 로빈슨 연구실, 방문교수 강직척추염 자가항체 연구
- 現 경희대 병원 류마티스내과 정교수
- 現 강동경희대 병원 류마티스 내과 과장, 경희대 의과대학 류마티스 실습학 책임교수

- 現 대한류마티스학회 정회원, 대한 내과학회 정회원, 대한골대사학회 정회원
- 現 대한류마티스학회 국제위원회 위원
- 現 식약처 한국의약품안전과리원 의약품 부작용 전문위원회 전문가단
- 現 의료기관평가인증원 환자안전 전문가 자문위원

Recent published articles (since 2013)

Song R, Lee S, Lee SH. Progressive sacroiliitis due to accessory sacroiliac joint mimicking ankylosing spondylitis: A case report. Medicine (Baltimore). 2019 Apr;98(16):e15324. doi: 10.1097/MD.0000000000015324.

Jung SW, Choi YY, Choi IS, Kim S, Jeong KH, Song R, Lee SH, Yang HI, Hong SJ,
Lee YA. Hypocomplementemic Urticarial Vasculitis Syndrome with Membranous
Nephropathy: Case Report. J Korean Med Sci. 2017 Dec;32(12):2064-2068. doi:
10.3346/jkms.2017.32.12.2064. PubMed PMID: 29115092; PubMed Central PMCID:
PMC5680509.

Song R, Chung SW, Lee SH. Radiographic Evidence of Hip Joint Recovery in
Patients with Ankylosing Spondylitis after Treatment with Anti-tumor Necrosis
Factor Agents: A Case Series. J Rheumatol. 2017 Nov;44(11):1759-1760. doi:
10.3899/jrheum.161401. PubMed PMID: 29093078.

Hwang JJ, Ahn J, Kim KP, Choi HI, Choi JY, Song R, Lee YA, Lee SH, Hong SJ,
Yang HI. Henoch-Schönlein Purpura With Muscle Involvement, Presenting as
Myositis. J Clin Rheumatol. 2017 Jan;23(1):60-62. doi:
10.1097/RHU.0000000000000476. PubMed PMID: 28002161.

Lee YH, Kim EY, Jeong da W, Kim YG, Lee SH, Song R, Yang HI, Lim SJ, Moon JY,
Lee SH. Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid
Deposit After Anti-Tumor Necrosis Factor α Therapy in a Patient With Ankylosing
Spondylitis. J Clin Rheumatol. 2016 Mar;22(2):86-8. doi:
10.1097/RHU.0000000000000356. PubMed PMID: 26906302.

Kim KS, You JS, Kim JY, Chang KJ, Yoo MC, Song R, Lee YA, Lee SH, Hong SJ,
Yang HI. Taurine ameliorates hypercholesterolemia but not obesity in rats fed a
lard-based, high-fat diet. Adv Exp Med Biol. 2015;803:271-8. doi:
10.1007/978-3-319-15126-7_22. PubMed PMID: 25833504.

Kim KS, Lee YA, Ji HI, Song R, Kim JY, Lee SH, Hong SJ, Yoo MC, Yang HI.
Increased expression of endocan in arthritic synovial tissues: effects of
adiponectin on the expression of endocan in fibroblast-like synoviocytes. Mol Med
Rep. 2015 Apr;11(4):2695-702. doi: 10.3892/mmr.2014.3057. PubMed PMID: 25483913.

Lee YA, Ji HI, Lee SH, Hong SJ, Yang HI, Chul Yoo M, Kim KS. The role of
adiponectin in the production of IL-6, IL-8, VEGF and MMPs in human endothelial
cells and osteoblasts: implications for arthritic joints. Exp Mol Med. 2014 Jan
17;46:e72. doi: 10.1038/emm.2013.141. PubMed PMID: 24434628; PubMed Central
PMCID: PMC3909890.

Kim KS, Ji HI, Chung H, Kim C, Lee SH, Lee YA, Yang HI, Yoo MC, Hong SJ.
Taurine chloramine modulates the expression of adipokines through inhibition of
the STAT-3 signaling pathway in differentiated human adipocytes. Amino Acids.
2013 Dec;45(6):1415-22. doi: 10.1007/s00726-013-1612-z. PubMed PMID: 24178768.

Ji HI, Lee SH, Song R, Yang HI, Lee YA, Hong SJ, Kim S, Park YB, Lee SK, Yoo
MC, Kim KS. Serum level of osteopontin as an inflammatory marker does not
indicate disease activity or responsiveness to therapeutic treatments in patients
with rheumatoid arthritis. Clin Rheumatol. 2014 Mar;33(3):397-402. doi:
10.1007/s10067-013-2375-3. PubMed PMID: 23995733.

Ko WJ, Kim KY, Kim SM, Hong SJ, Lee SH, Song R, Yang HI, Lee YA. A case of
myotonic dystrophy with electrolyte imbalance. J Korean Med Sci. 2013
Jul;28(7):1111-3. doi: 10.3346/jkms.2013.28.7.1111. PubMed PMID: 23853500; PubMed
Central PMCID: PMC3708088.

Kim KS, Choi HM, Ji HI, Kim C, Kim JY, Song R, Kim SM, Lee YA, Lee SH, Yang
HI, Yoo MC, Hong SJ. Effect of taurine chloramine on differentiation of human
preadipocytes into adipocytes. Adv Exp Med Biol. 2013;775:247-57. doi:
10.1007/978-1-4614-6130-2_21. PubMed PMID: 23392940.

Lee SH, Lee EJ, Chung SW, Song R, Moon JY, Lee SH, Lim SJ, Lee YA, Hong SJ,
Yang HI. Renal involvement in ankylosing spondylitis: prevalence, pathology,
response to TNF-a blocker. Rheumatol Int. 2013 Jul;33(7):1689-92. doi:
10.1007/s00296-012-2624-9. PubMed PMID: 23269570.

Hwang HJ, Kim JI, Lee SH, Park CB, Sohn IS. Full-blown cardiac manifestations in ankylosing spondylitis. Echocardiography. 33(11):1785-1787 2016 Nov

Kim HW, Kwon SR, Jung KH, Kim SK, Baek HJ, Seo MR, Bang SY, Lee HS, Suh CH, Jung JY, Son CN, Shim SC, Lee SH, Lee SG, Lee YA, Lee EY, Kim TH, Kim YG; Safety of Resuming Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis Patients Concomitant with the Treatment of Active Tuberculosis: A Retrospective Nationwide Registry of the Korean Society of Spondyloarthritis Research. PLoS One 11(4) 2016 Apr

Won KY, Park SY, Lee SH Subcutaneous Sarcoidosis Mimicking Cellulitis. J Rheumatol.
43(3):674-5. 2016 Mar

글로벌 신약 임상연구 (책임연구자) Clinical trials with Grant(P.I)

1. Principal Investigator: A multicenter, randomomized, double-blind, active-controlled, parallel group, Phase III trial to evaluate the equivalence in efficacy and safety of HD203 25mg and Enbrel 25mg in Combination with methotrexate in patients with Rheumatid Arthritis; HERA Study. 2007~2012
2. Principal Investigator: A multicenter, prospective cohort, Phase IV trial to evaluate the efficacy and safety of Remsima in patients with Ankylosing sdpondylitis. Sep, 2014~2017
3. Principal Investigator: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Ankylosing spondylitis; Phase 3. Feb, 2015~2017
4. Principal Investigator: A prospective, Mono-Country, Multi-Center Study to observe the frequency of Extra-Axial symptoms in Korean Ankylosing Spondylitis patients on adalimumab Therapy; Dec, 2014~
5. Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naïve Subjects With Active Radiographic Axial Spondyloarthritis; Sep, 2015~2017
6. Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naïve Subjects With Active non-Radiographic Axial Spondyloarthritis; Sep, 2015~2017
7. Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα failure Subjects With Active Radiographic Axial Spondyloarthritis; Sep, 2015~2017
8. Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ixekizumab in the Treatment of Anti-TNFα Naïve Subjects With Active Radiographic Axial Spondyloarthritis; Apr, 2016~
9. Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ixekizumab in the Treatment of Anti-TNFα failure Subjects With Active Radiographic Axial Spondyloarthritis; Apr, 2016~
10. Principal Investigator: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ixekizumab in the Treatment of Anti-TNFα Naïve Subjects With Active non-Radiographic Axial Spondyloarthritis; Apr, 2016~
11. Principal Investigator: A Phase 3, Multicenter, Long-Term Extension Study of 104 Weeks, Including a, Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients with Axial Spondyloarthritis; Apr, 2017~
12. Principal Investigator: A phase 2B, A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects with Active Ankylosing Spondylitis; Nov, 2017~
13. A randomized, partially-blinded, active-controlled multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy up to 2 years in patients with active ankylosing spondylitis; Oct, 2018~